US FDA to discuss Menaflex device, gives more time for feedback on 510(k) process
This article was originally published in SRA
Executive Summary
The Orthopaedic and Rehabilitation Devices Panel of the US Food and Drug Administration’s Medical Devices Advisory Committee will meet on 23 March to discuss and make recommendations on the agency’s re-evaluation of ReGen Biologic’s collagen scaffold device, Menaflex1.